ClinicalTrials.gg
RecruitingNCT07663539Updated Jul 28, 2026

Insights From Bereaved Parents and Oncologists

An observational study in Communication, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by St. Jude Children's Research Hospital · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Investigators want to find better ways for doctors and families to talk about cancer and how uncertainty may affect a child's life.

Read the detailed description

Primary Objective

  • To characterize how bereaved parents of children with cancer and their child's oncologist perceive their experience with communication about prognostic uncertainty during the child's cancer journey and during bereavement.

Secondary Objective

  • To elicit parents' and oncologists' preferences and recommendations for how clinicians should talk with children and families about prognosis in the setting of uncertainty.

This study aims to explore bereaved parents' and oncologists' reflections on communication about prognostic uncertainty during the child's cancer treatment. Parents who have lost a child to cancer and the doctors who treated them will be invited to join this study.

Participants who opt to participate in the study will engage in an audio recorded semi-structured interview with a researcher, virtually or in person (at their discretion) to share their perspectives and recommendations based on their experience. Throughout the interview, the interviewer has the option to ask additional questions (i.e., probe with questions not in the interview guide) to respond to comments made by the participant and honor the topics of interest to that given participant. The participant will be provided an opportunity to add any details or comments at the end of the interview if he/she would like to share additional information.

Following completion of the qualitative portion of the interview, the researcher will ask the participant several questions from a demographic form. The demographic form will include questions related to participant age, race/ethnicity, state/country of residence for bereaved parents, and years of clinical practice for oncologists.

02

Conditions studied

  • Communication

Browse trials for

Keywords

  • Prognostic Uncertainty
  • Bereaved Parents
  • Oncologist
03

In context

Communication

719 studies on the registry are indexed under Communication; 159 are open to participants now.

This study's planned enrollment of 50 is below the median of 104 across 132 observational studies indexed under Communication.

Browse Communication studies →

Lead sponsor

St. Jude Children's Research Hospital is the lead sponsor of 440 studies on the registry; 102 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Parents who have lost a child to cancer and the doctors who treated them.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must be ≥ 18 years of age or legally emancipated
  • Parent Participants must have a child who:

    • Received cancer care from a clinician at St. Jude, as documented in the electronic medical record, AND
    • Died at least 6 months prior to enrollment, but no more than 24 months prior to enrollment.
  • Oncologist participants at St. Jude must:

    • Be listed as the primary oncologist as documented in the electronic medical record, AND
    • Have the respective patient's parent agreement to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Declining, refusal, or unwillingness to participate
  • Inability or unwillingness of research participant to give .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parent Participants

    Parents who have lost a child to cancer

  • Oncologist Participants

    St. Jude doctors who treated the child

06

What researchers measure

Primary outcomes

  1. Bereaved parents of children with cancer and oncologists reflections on communication about prognostic uncertainty during the child's cancer treatment

    The analysis plan for this study is to apply reflexive thematic analysis as described by Braun and Clarke, involving the following six step process: 1. Familiarization with the data, 2. Generating initial codes, 3. Generating initial themes, 4. Reviewing themes, 5. Refining, defining, and naming themes, 6. Writing up a narrative of results. Investigators will conduct individual interviews with participants and code transcripts independently to identify salient themes from each cohort, subsequently compare codes across cohorts to explore and characterize areas of convergence and divergence and use a matrix approach to facilitate this comparative analysis. Interviews will be recorded, transcribed, and de-identified prior to analysis. MAXQDA, a sophisticated qualitative analysis software system, will be used to conduct and synthesize analysis.

    Time frame: Approximately 1-3 weeks after enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07663539
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 9, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Stephanie Gehle, MD
Contact
referralinfo@stjude.org
888-226-4343
Stephanie Gehle, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion